Evercore Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $60

Evercore维持Moderna(MRNA.US)持有评级，下调目标价至60美元

moomoo资讯 · 10/28 08:31 · 评级/大行评级

Evercore analyst Cory Kasimov maintains $Moderna (MRNA.US)$ with a hold rating, and adjusts the target price from $105 to $60.

According to TipRanks data, the analyst has a success rate of 56.0% and a total average return of 20.0% over the past year.

AnalystRecentRatingAutoNews_76721001012871_20241028_0eb81c3c4154edcff75872a4d9768a16b0d3a4aa_1730136658212908_mm_en

Furthermore, according to the comprehensive report, the opinions of $Moderna (MRNA.US)$'s main analysts recently are as follows:

Moderna's stock performance has been challenged with a 50% decline since the start of the year, amidst uncertainties surrounding future revenues from respiratory vaccines. Nevertheless, there is potential for growth from pipeline programs. The anticipation of cytomegalovirus Phase 3 results by the end of the year is seen as a key driver for the stock's recovery and a significant indicator for the company's wider latent virus portfolio.
After conducting an exhaustive review of the model and considering the guidance reductions announced during R&D Day, along with the projected vaccination trends for Fall 2024, it's evident that investor sentiment remains low. The market's attention is concentrated on the changing dynamics of COVID and RSV, as well as the factors that could potentially lead to a positive shift.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Evercore分析师Cory Kasimov维持$Moderna (MRNA.US)$持有评级，并将目标价从105美元下调至60美元。

根据TipRanks数据显示，该分析师近一年总胜率为56.0%，总平均回报率为20.0%。

AnalystRecentRatingAutoNews_76721001012871_20241028_0eb81c3c4154edcff75872a4d9768a16b0d3a4aa_1730136658212908_mm_sc

此外，综合报道，$Moderna (MRNA.US)$近期主要分析师观点如下：

由于呼吸疫苗未来收入的不确定性，Moderna的股票表现受到挑战，自年初以来下跌了50％。尽管如此，管道项目仍有增长的潜力。对巨细胞病毒第三阶段业绩的预期被视为该股复苏的关键驱动力，也是该公司更广泛的潜在病毒投资组合的重要指标。
在对该模型进行了详尽的审查并考虑了研发日期间宣布的指导削减措施以及2024年秋季的预计疫苗接种趋势之后，很明显，投资者的情绪仍然很低。市场的注意力集中在COVID和RSV不断变化的动态上，以及可能导致积极转变的因素上。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Evercore Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $60

Evercore Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $60

风险及免责提示

声明